Robert W. Baird Issues Positive Forecast for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its target price boosted by analysts at Robert W. Baird from $85.00 to $92.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird‘s price target points to a potential upside of 17.23% from the stock’s current price.

A number of other equities research analysts also recently weighed in on TEM. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Lake Street Capital cut Tempus AI to a “hold” rating in a report on Monday, July 20th. UBS Group started coverage on Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price for the company. The Goldman Sachs Group initiated coverage on Tempus AI in a research note on Monday, September 21st. They issued a “neutral” rating and a $75.00 price target on the stock. Finally, Roth Capital assumed coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $79.37.

Tempus AI Price Performance

NASDAQ TEM opened at $78.48 on Tuesday. Tempus AI has a twelve month low of $40.77 and a twelve month high of $90.53. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The stock has a market capitalization of $14.16 billion, a PE ratio of -54.50 and a beta of 3.54. The stock has a 50-day simple moving average of $70.80 and a 200 day simple moving average of $57.12.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s revenue was up 23.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.46) EPS. Research analysts anticipate that Tempus AI will post -1.45 EPS for the current year.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the transaction, the executive vice president directly owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This trade represents a 13.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Rogers sold 26,313 shares of Tempus AI stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at approximately $6,361,440. This trade represents a 19.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,256,777 shares of company stock worth $86,356,352 in the last quarter. 24.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Guardian Partners Inc. grew its position in shares of Tempus AI by 8.3% in the 3rd quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock valued at $213,000 after purchasing an additional 200 shares during the period. Kestra Private Wealth Services LLC raised its holdings in Tempus AI by 1.4% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 18,685 shares of the company’s stock worth $1,530,000 after buying an additional 257 shares during the period. V Square Quantitative Management LLC acquired a new stake in Tempus AI during the 3rd quarter worth approximately $27,000. ProShare Advisors LLC lifted its stake in Tempus AI by 5.9% in the third quarter. ProShare Advisors LLC now owns 6,500 shares of the company’s stock valued at $532,000 after buying an additional 360 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC lifted its stake in Tempus AI by 6.7% in the third quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock valued at $525,000 after buying an additional 400 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.